TY - JOUR
T1 - Is Additional Surgery Always Sufficient for Preventing Recurrence After Endoscopic Submucosal Dissection with Curability C-2 for Early Gastric Cancer?
AU - Hatta, Waku
AU - Gotoda, Takuji
AU - Oyama, Tsuneo
AU - Kawata, Noboru
AU - Takahashi, Akiko
AU - Oka, Shiro
AU - Hoteya, Shu
AU - Nakagawa, Masahiro
AU - Hirano, Masaaki
AU - Esaki, Mitsuru
AU - Matsuda, Mitsuru
AU - Ohnita, Ken
AU - Shimoda, Ryo
AU - Yoshida, Motoyuki
AU - Dohi, Osamu
AU - Takada, Jun
AU - Tanaka, Keiko
AU - Yamada, Shinya
AU - Tsuji, Tsuyotoshi
AU - Ito, Hirotaka
AU - Aoyagi, Hiroyuki
AU - Nakamura, Tomohiro
AU - Nakaya, Naoki
AU - Shimosegawa, Tooru
AU - Masamune, Atsushi
N1 - Funding Information:
The authors thank Hiroyuki Ono (Shizuoka Cancer Center), Koki Nakamura (Hiroshima City Hospital), Naohiko Harada (National Hospital Organization Kyushu Medical Center), Yasumasa Hara (Toyama Prefectural Central Hospital), and Kohei Yamanouchi (Saga Medical School) for the enrollment of patients and data collection.
Publisher Copyright:
© 2019, Society of Surgical Oncology.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Background: When a lesion does not meet the curative criteria of endoscopic submucosal dissection (ESD) for early gastric cancer (EGC), referred to as non-curative resection or curability C-2 in the guidelines, an additional surgery is the standard therapy because of the risk of lymph node metastasis (LNM). Objective: This study aimed to identify high-risk patients for recurrence after additional surgery for curability C-2 ESD of EGC. Methods: This multicenter retrospective cohort study enrolled 1064 patients who underwent additional surgery after curability C-2 ESD for EGC. We evaluated the recurrence rate and the risk factors for recurrence after additional surgery in these patients. Results: The 5-year recurrence rate after additional surgery was 1.3%. Multivariate Cox analysis revealed that the independent risk factors for recurrence after additional surgery were LNM (hazard ratio [HR] 32.47; p < 0.001) and vascular invasion (HR 4.75; p = 0.014). Moreover, patients with both LNM and vascular invasion had a high rate of recurrence after additional surgery (24.6% in 5 years), with a high HR (119.32) compared with those with neither LNM nor vascular invasion. Among patients with no vascular invasion, a high rate of recurrence was observed in those with N2/N3 disease according to the American Joint Committee on Cancer TNM staging system (27.3% in 5 years), in contrast with no recurrence in those with N1 disease. Conclusions: Patients with both LNM (N1–N3) and vascular invasion, as well as those with N2/N3 disease but no vascular invasion, would be candidates for adjuvant chemotherapy after additional surgery for curability C-2 ESD of EGC.
AB - Background: When a lesion does not meet the curative criteria of endoscopic submucosal dissection (ESD) for early gastric cancer (EGC), referred to as non-curative resection or curability C-2 in the guidelines, an additional surgery is the standard therapy because of the risk of lymph node metastasis (LNM). Objective: This study aimed to identify high-risk patients for recurrence after additional surgery for curability C-2 ESD of EGC. Methods: This multicenter retrospective cohort study enrolled 1064 patients who underwent additional surgery after curability C-2 ESD for EGC. We evaluated the recurrence rate and the risk factors for recurrence after additional surgery in these patients. Results: The 5-year recurrence rate after additional surgery was 1.3%. Multivariate Cox analysis revealed that the independent risk factors for recurrence after additional surgery were LNM (hazard ratio [HR] 32.47; p < 0.001) and vascular invasion (HR 4.75; p = 0.014). Moreover, patients with both LNM and vascular invasion had a high rate of recurrence after additional surgery (24.6% in 5 years), with a high HR (119.32) compared with those with neither LNM nor vascular invasion. Among patients with no vascular invasion, a high rate of recurrence was observed in those with N2/N3 disease according to the American Joint Committee on Cancer TNM staging system (27.3% in 5 years), in contrast with no recurrence in those with N1 disease. Conclusions: Patients with both LNM (N1–N3) and vascular invasion, as well as those with N2/N3 disease but no vascular invasion, would be candidates for adjuvant chemotherapy after additional surgery for curability C-2 ESD of EGC.
UR - http://www.scopus.com/inward/record.url?scp=85069700817&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069700817&partnerID=8YFLogxK
U2 - 10.1245/s10434-019-07579-2
DO - 10.1245/s10434-019-07579-2
M3 - Article
C2 - 31342376
AN - SCOPUS:85069700817
SN - 1068-9265
VL - 26
SP - 3636
EP - 3643
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 11
ER -